Navigation Links
Boston Scientific Carotid WALLSTENT® Found Safe in Study of High Surgical Risk Patients in Routine Clinical Practice
Date:11/8/2011

NATICK, Mass. and SAN FRANCISCO, Nov. 8, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) reports positive outcomes from the CABANA post-approval study of the  Carotid WALLSTENT® Monorail® Endoprosthesis used in conjunction with its FilterWire EZ™ Embolic Protection System in routine clinical practice.  Multi-center registry results demonstrate that carotid artery stenting (CAS) with Carotid WALLSTENT and FilterWire EZ is a safe alternative to carotid endarterectomy (CEA) in patients with carotid artery stenosis who are at increased risk for surgery.  The analysis was presented today by L. Nelson Hopkins, M.D., Chairman of Neurosurgery at the State University of New York in Buffalo, Trial Investigator and Advisory Committee member, at the Cardiovascular Research Foundation's annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium in San Francisco.

The CABANA study enrolled 1,097 patients at 99 sites in the U.S.  Within the patient population, 32.7 percent were symptomatic and 67.3 percent were asymptomatic for carotid artery disease.  All patients were at high risk for CEA, the standard surgical treatment for carotid stenosis, due to pre-specified anatomical criteria and/or medical comorbidities.  The primary endpoint of 30-day composite rate of major adverse events (MAE), which included stroke, death and myocardial infarction (MI), was 4.6 percent.  The 30-day stroke rate was 3.3 percent, with the majority of strokes being ipsilateral (occurring on same side as blockage) and ischemic (resulting from lack of blood flow).  Overall mortality was 1.3 percent and the rate of MI was 0.5 percent at 30 days.  Technical success was achieved in 97.1 percent of patients.  Follow-up at 30 days included clinical evaluation and independent neurologic and National Institutes of Health (NIH) stroke scale assessments.

"Results from this post-approval study show low rates of stroke, death, and MI, demonstrating that the Carotid WALLSTENT and FilterWire EZ can be used in carotid stenting procedures as a safe alternative to surgery in high-risk patients," said Dr. Hopkins.  "In my clinical practice, I have found that the user-friendly design of this stenting system contributes to successful outcomes in patients with carotid artery stenosis at increased risk for surgery."

The Carotid WALLSTENT Monorail Endoprosthesis is a self-expanding stent with a closed-cell design to provide increased scaffolding for improved lesion coverage and a smooth inner lumen.  It features a highly flexible, low-profile stent delivery system designed to provide exceptional tracking through difficult anatomy.  The FilterWire EZ Embolic Protection System is designed to capture plaque debris that may be released during a procedure, preventing it from traveling to the brain, where it could cause a stroke.  The Carotid WALLSTENT Monorail Endoprosthesis is the leading carotid stent in Europe and is available in all major markets worldwide."As public discussion continues regarding carotid stenosis therapy, the CABANA study demonstrates our commitment to providing physicians with safe and effective CAS treatment options supported by strong clinical evidence," said Jeff Mirviss, President of Boston Scientific's Peripheral Interventions business.  "The Carotid WALLSTENT and FilterWire EZ System offer a less-invasive alternative for treating carotid artery disease and can help reduce the risk of stroke, which can have devastating consequences on patients and their families."

The U.S. Food and Drug Administration (FDA) approved the Carotid WALLSTENT in 2008.  The FilterWire EZ Embolic Protection System received FDA clearance for use in carotid artery stenting procedures in 2006.  

About Carotid Artery DiseaseThe carotid arteries, located on either side of the neck, are the main conduit for blood supply to the brain.  Plaque formation in these arteries can lead to carotid artery disease, which puts patients at increased risk for stroke.  Patients with carotid artery disease are typically treated with carotid endarterectomy, a surgical procedure involving an incision in the neck and removal of plaque from the vessel walls.  Carotid artery stenting is a less-invasive alternative in which a stent is delivered to the blocked site and expanded, forcing open the artery walls and restoring adequate blood flow.  

About Boston ScientificBoston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties.  For more information, please visit: www.bostonscientific.com.  

Cautionary Statement Regarding Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words.  These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance.  These forward-looking statements include, among other things, statements regarding our business plans, our Carotid WALLSTENT® Monorail® Endoprosthesis and FilterWire EZ™ Embolic Protection System, clinical trials, product performance and effects and competitive offerings.  If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements.  These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release.  As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.  

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and future business decisions made by us and our competitors.  All of these factors are difficult or impossible to predict accurately and many of them are beyond our control.  For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A – Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A – Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter.  We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.  This cautionary statement is applicable to all forward-looking statements contained in this document.CONTACT:

Erik Kopp508-650-8660 (office)Media RelationsBoston Scientific Corporationerik.kopp@bsci.comDavid Knutson (attending TCT)651-260-8288 (mobile)Media Relations Boston Scientific Corporationdavid.knutson@bsci.comSean Wirtjes508-652-5305 (office)Investor RelationsBoston Scientific Corporationinvestor_relations@bsci.com
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Boston Scientifics PROMUS Element™ Platinum Chromium Stent Demonstrates Excellent Outcomes in Patients With Long Coronary Lesions
2. Boston Scientific Announces Schedule of Events at TCT Scientific Symposium
3. Boston Scientific Exceeds Third Quarter EPS Guidance, Repurchases 30 Million Shares
4. Boston Scientific Completes Enrollment in Benign Stricture Study of WallFlex® Biliary RX Stent
5. Boston Scientific Launches Promus Element™ Stent System In China
6. Boston Scientific Welcomes Introduction of Medical Device Regulatory Improvement Act in U.S. Senate
7. Boston Scientific To Webcast Conference Call Discussing Third Quarter 2011 Financial Results
8. COPAN WASP® Lands at Prestigious Boston Medical Center
9. Boston Scientific Begins Enrollment in NECTAR-HF Clinical Trial
10. Boston Scientific Announces Favorable Appellate Court Ruling Affirming Non-Infringement of Johnson & Johnson Patent
11. Bluestar Silicones to Present Antimicrobial Silicones at Medical Silicones Conference in Boston
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... , Jan. 18, 2017  Tarix Orphan LLC ... has granted a Rare Pediatric Disease (RPD) designation for ... Recessive Dystrophic Epidermolysis Bullosa (RDEB), a rare genetic skin ... and treatment is limited to supportive care. ... Orphan Drug Designation previously granted by the FDA in ...
(Date:1/18/2017)... January 18, 2017 ML ... plans to publish an online presentation tomorrow, January ... sales forecast for 2017. Management reports that the ... record sales performance from its existing operations, and ... entry into the Cannabis sector through a ...
(Date:1/18/2017)... --  Robust competition in the private marketplace is resulting ... according to a new study by the ... first to examine the share of prescription medicine spending ... (PBMs), health plans and other stakeholders in the supply ... to show what happens when the list price of ...
Breaking Medicine Technology:
(Date:1/17/2017)... ... ... For breast cancer clinicians and researchers who were unable to attend the ... review and analysis of its highlights, a novel half-day, complimentary meeting—the 14th Annual Best ... February 4, 2017 in Chicago. Chaired by Kathy S. Albain, MD, FACP, FASCO from ...
(Date:1/17/2017)... ... 2017 , ... SunView Software’s Service Smart Technology has been selected as a ... , Each year, Pink Elephant recognizes a new product or service developed by an ... problem or opportunity. The award highlights original innovations that were released in 2016, either ...
(Date:1/17/2017)... Chapel, Florida (PRWEB) , ... January 17, 2017 ... ... Connected City, a new 21st century approach to infusing high speed technology into ... an area exclusively dedicated to the advancement of healthcare and wellness in a ...
(Date:1/17/2017)... , ... January 17, 2017 , ... ... online continuing education for EMS and firefighting professionals, has released four new continuing ... These new courses are taught live in an online classroom and meet the ...
(Date:1/17/2017)... OAKLAND, CA (PRWEB) , ... January 17, 2017 , ... ... been named winners of the fourth Cradle to Cradle Product Design Challenge , ... the fourth in a series of six circular design challenges scheduled to run through ...
Breaking Medicine News(10 mins):